These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27211612)

  • 41. A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II.
    Okuyama T; Eto Y; Sakai N; Nakamura K; Yamamoto T; Yamaoka M; Ikeda T; So S; Tanizawa K; Sonoda H; Sato Y
    Mol Ther; 2021 Feb; 29(2):671-679. PubMed ID: 33038326
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Validation of a heparan sulfate-derived disaccharide as a marker of accumulation in murine mucopolysaccharidosis type IIIA.
    King B; Savas P; Fuller M; Hopwood J; Hemsley K
    Mol Genet Metab; 2006 Feb; 87(2):107-12. PubMed ID: 16352454
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial.
    Tardieu M; Zérah M; Husson B; de Bournonville S; Deiva K; Adamsbaum C; Vincent F; Hocquemiller M; Broissand C; Furlan V; Ballabio A; Fraldi A; Crystal RG; Baugnon T; Roujeau T; Heard JM; Danos O
    Hum Gene Ther; 2014 Jun; 25(6):506-16. PubMed ID: 24524415
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial.
    Tardieu M; Zérah M; Gougeon ML; Ausseil J; de Bournonville S; Husson B; Zafeiriou D; Parenti G; Bourget P; Poirier B; Furlan V; Artaud C; Baugnon T; Roujeau T; Crystal RG; Meyer C; Deiva K; Heard JM
    Lancet Neurol; 2017 Sep; 16(9):712-720. PubMed ID: 28713035
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial.
    Okuyama T; Eto Y; Sakai N; Minami K; Yamamoto T; Sonoda H; Yamaoka M; Tachibana K; Hirato T; Sato Y
    Mol Ther; 2019 Feb; 27(2):456-464. PubMed ID: 30595526
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Defective heparan sulfate metabolism in the Sanfilippo syndrome and assay of this defect in the assessment of the mucopolysaccharidoses patient.
    Gordon BA; Feleki V; Budreau CH; Tyler L
    Clin Biochem; 1975 Jun; 8(3):184-93. PubMed ID: 238759
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder.
    King B; Setford ML; Hassiotis S; Trim PJ; Duplock S; Tucker JN; Hattersley K; Snel MF; Hopwood JJ; Hemsley KM
    Exp Neurol; 2016 Apr; 278():11-21. PubMed ID: 26626972
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease.
    Hemsley KM; Luck AJ; Crawley AC; Hassiotis S; Beard H; King B; Rozek T; Rozaklis T; Fuller M; Hopwood JJ
    Eur J Neurosci; 2009 Mar; 29(6):1197-214. PubMed ID: 19302155
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA.
    Rozaklis T; Beard H; Hassiotis S; Garcia AR; Tonini M; Luck A; Pan J; Lamsa JC; Hopwood JJ; Hemsley KM
    Exp Neurol; 2011 Jul; 230(1):123-30. PubMed ID: 21515264
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety evaluation of chronic intrathecal administration of heparan N-sulfatase in juvenile cynomolgus monkeys.
    Pfeifer RW; Felice BR; Boyd RB; Butt MT; Ruiz JA; Heartlein MW; Calias P
    Drug Deliv Transl Res; 2012 Jun; 2(3):187-200. PubMed ID: 25786866
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mild mental retardation and low levels of urinary heparan sulfate in a patient with the attenuated phenotype of mucopolysaccharidosis type IIIA.
    Coppa GV; Galeotti F; Zampini L; Galeazzi T; Padella L; Santoro L; Maccari F; Gabrielli O; Volpi N
    Clin Biochem; 2013 May; 46(7-8):688-90. PubMed ID: 23274385
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Brain Targeting in MPS-IIIA.
    Sorrentino NC; Fraldi A
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():630-8. PubMed ID: 27491210
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice.
    Gliddon BL; Hopwood JJ
    Pediatr Res; 2004 Jul; 56(1):65-72. PubMed ID: 15128919
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of Trehalose Administration in Patients with Mucopolysaccharidosis Type III.
    Mobini M; Radbakhsh S; Kubaski F; Eshraghi P; Vakili S; Vakili R; Abbasifard M; Jamialahmadi T; Rajabi O; Emami SA; Tayarani-Najaran Z; Rizzo M; Eid AH; Banach M; Sahebkar A
    Curr Med Chem; 2024; 31(20):3033-3042. PubMed ID: 37038706
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications.
    Yogalingam G; Hopwood JJ
    Hum Mutat; 2001 Oct; 18(4):264-81. PubMed ID: 11668611
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Elevated cerebral spinal fluid biomarkers in children with mucopolysaccharidosis I-H.
    Raymond GV; Pasquali M; Polgreen LE; Dickson PI; Miller WP; Orchard PJ; Lund TC
    Sci Rep; 2016 Dec; 6():38305. PubMed ID: 27910891
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intrathecal enzyme replacement for cognitive decline in mucopolysaccharidosis type I, a randomized, open-label, controlled pilot study.
    Chen AH; Harmatz P; Nestrasil I; Eisengart JB; King KE; Rudser K; Kaizer AM; Svatkova A; Wakumoto A; Le SQ; Madden J; Young S; Zhang H; Polgreen LE; Dickson PI
    Mol Genet Metab; 2020 Feb; 129(2):80-90. PubMed ID: 31839529
    [TBL] [Abstract][Full Text] [Related]  

  • 58. First-in-Man Intrathecal Application of Neurite Growth-Promoting Anti-Nogo-A Antibodies in Acute Spinal Cord Injury.
    Kucher K; Johns D; Maier D; Abel R; Badke A; Baron H; Thietje R; Casha S; Meindl R; Gomez-Mancilla B; Pfister C; Rupp R; Weidner N; Mir A; Schwab ME; Curt A
    Neurorehabil Neural Repair; 2018 Jun; 32(6-7):578-589. PubMed ID: 29869587
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III.
    de Ruijter J; de Ru MH; Wagemans T; Ijlst L; Lund AM; Orchard PJ; Schaefer GB; Wijburg FA; van Vlies N
    Mol Genet Metab; 2012 Dec; 107(4):705-10. PubMed ID: 23084433
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Delivery of therapeutic protein for prevention of neurodegenerative changes: comparison of different CSF-delivery methods.
    Marshall NR; Hassiotis S; King B; Rozaklis T; Trim PJ; Duplock SK; Winner LK; Beard H; Snel MF; Jolly RD; Hopwood JJ; Hemsley KM
    Exp Neurol; 2015 Jan; 263():79-90. PubMed ID: 25246230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.